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Vein bypass grafting is a mainstay of therapy for
patients with coronary and peripheral atherosclerosis.
Demographic trends and increased longevity in the
US population are likely to result in a continued
growth in demand for these interventions. More
than 50% of aortocoronary vein bypass grafts fail
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Purpose: Gene transfer offers the potential to modify vein graft biology at the time of
surgical implantation. Efficiency of gene delivery, stability of expression, and host
responses are critical parameters for candidate vectors. We compared the effects of intra-
luminal exposure with adenovirus (AD) and adeno-associated virus (AAV) vectors on
transgene expression and monocyte adhesion (MA) in treated vein segments.
Methods: Adult New Zealand white rabbits (N = 51) were anesthetized, and the jugular
veins were cannulated bilaterally. Veins were gently distended with either vector (2·108
to 1·1010 infective particles/mL) or vehicle (control) for 30 minutes, after which venous
flow was restored. AD and AAV vectors encoding for the marker genes β-galactosidase
(LacZ) and green fluorescent protein (GFP) were used. Vessels were explanted 2 to 40
days postinfection for analysis of gene expression (X-gal staining, reverse transcriptase-
polymerase chain reaction), MA, and immunohistochemistry. Ex vivo adhesion assays
used 51Cr-labeled THP-1 cells. Statistical significance was tested by using analysis of
variance with a P value less than .05.
Results: All animals survived, and all treated veins were patent at sacrifice. Intraluminal
exposure to AD at a titer of 1·109 resulted in near complete transduction of the endothe-
lium at 2 days, with no detectable expression by day 14. At an equal titer of infectious
particles, transgene expression was markedly less for AAV at 2 to 7 days, but improved
at 2 weeks and persisted to 40 days. MA was significantly increased 2 days after AD
exposure (2.7-fold vs control, *P < .002); AAV treatment had no discernible effect 
on MA.
Conclusion: AD-mediated gene transfer to vein segments resulted in robust, transient
gene expression that disappeared after 2 weeks. In comparison, AAV-mediated gene
delivery was less efficient, but resulted in delayed onset, persistent expression beyond 30
days. AD exposure induced an early increase in MA to the vein surface that was not seen
with AAV treatment. Current generations of both AD and AAV vectors have significant,
albeit different, limitations for vascular gene therapy. (J Vasc Surg 2000;31:1149-59.)
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within 10 years,1,2 frequently requiring a second
operation. In the lower extremities, 5-year patency
rates for saphenous vein grafts are in the range of 70%
to 80%3; however, results are notably worse for alter-
native vein conduits or redo grafts (40%-60%).4-6
Currently, prosthetic alternatives for small caliber
arterial reconstructions remain markedly inferior to
autogenous vein, underscoring the importance of
optimizing vein use and durability.7 Pharmacologic
approaches to improve vein graft patency, in particu-
lar the use of antiplatelet or anticoagulant regimens,
have met with limited success. The development of
gene transfer technology offers the potential to mod-
ify vein graft biology at the molecular level.
Since the development of recombinant viral-
based vector systems in the 1980s, the therapeutic
application of gene transfer has reached clinical real-
ity. In the cardiovascular system, a variety of vectors
have been examined for efficacy of gene delivery,
duration of gene expression, and host responses.8,9
The ideal vector would be easily prepared, stored,
and handled; be capable of efficient delivery to the
normally quiescent target cells of the vasculature;
elicit little or no inflammatory response; and allow
for durable (and preferably regulatable) transgene
expression. Recombinant adenoviral (AD) vectors
may be prepared and stored at adequate titer and are
capable of efficient delivery to quiescent cells; how-
ever, currently available AD vectors are severely lim-
ited by the transient nature of gene expression and
the marked host-immune responses that they elic-
it.10,11 Recombinant adeno-associated virus (AAV),
a nonpathogenic, single-strand DNA virus, offers a
number of attractive features as a candidate vector.
In particular, animal studies with AAV vectors for
delivery to muscle, liver, or central nervous system
tissues have been notable for a relative lack of
immunogenicity and durability of gene expression
for months and even years after exposure.12-15
Relatively few studies have examined the cardiovas-
cular application of AAV, in particular its suitability
for intraoperative modification of vein grafts.
These investigations evaluated the potential
application of AAV for genetic modification of veins
used for grafting. Rabbit jugular veins were exposed
in situ to vectors administered intraluminally. We
compared transgene delivery, kinetics of expression,
and local inflammatory responses to AD and AAV
vectors. The results highlight the different potential
uses and limitations of the two vectors for this appli-
cation and support continued efforts in vector devel-
opment designed to address these specific short-
comings.
METHODS
Vector construction and viral preparations.
Vector preparations were provided by the Vector
Core Laboratory of Professor Richard C. Mulligan
(Harvard Medical School). Recombinant AD
(serotype 5) vectors are E1, E3 deleted, with the
transgene cassette inserted into the E1 region of the
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Fig 1. Schematic representation of transgene constructs used. Adenovirus (Ad)
constructs were inserted into the E1 region of an E1, E3-deleted adenoviral
backbone (36 kB). Adeno-associated virus (AAV) constructs are inserted
between the AAV inverted terminal repeats, replacing the AAV coding
sequences (4.7 kB).
AD genome. AAV vectors derive from AAV serotype
2, with the transgene cassette replacing all the cod-
ing region, flanked by the inverted terminal repeats
(ITRs). The transgene constructs encoding the
reporter genes LacZ (codes for β-D-galactosidase)
and GFP (codes for green fluorescent protein) used
in these studies are schematically illustrated in Fig 1
and were designed and constructed in the Mulligan
laboratory. All four of the constructs use the
cytomegalovirus (CMV) immediate-early promoter.
Methods used for recombinant AD and AAV prepa-
rations are described in detail elsewhere.16,17
Titering of AAV was performed by using an infec-
tious center assay,18 which correlates with the num-
ber of transducing viral particles; AD vectors were
titered by standard plaque assay on 293 cells.
Concentrated viral supernatants obtained from
the vector core laboratory were stored at –80°C and
thawed immediately before use. At the time of sur-
gical vein exposure, vectors were diluted to their
final concentration in culture medium (M-199,
GIBCO, Grand Island, NY) and 400 µL aliquots
kept on ice until use.
Animal procedures
The animal experimentation protocol was
reviewed and approved by the Harvard Medical Area
Standing Committee on Animals. Animal care and
procedures were in accordance with the “Guide for
the Care and Use of Laboratory Animals” (Institute
of Laboratory Animal Resources, Commission 
on Life Sciences, National Research Council,
Washington: National Academy Press, 1996).
In vivo gene transfer. New Zealand white rab-
bits (weight range, 3.0-3.5 kg; N = 51) were given
chow and water ad libitum. On the day of virus
infection, animals were anesthetized with xylazine
(5 mg/kg; Henry Schein, Port Washington, NY)
and ketamine (25 mg/kg; Henry Schein) intra-
muscularly, and an intravenous catheter was insert-
ed into a marginal ear vein. Anesthesia was main-
tained by means of an intermittent intravenous
injection of xylazine (0.5 mg/mL) and ketamine
(10 mg/mL). A midline neck incision was made,
and each common jugular (CJ) vein and its branch-
es were identified. Side branches were carefully lig-
ated to create an isolated segment of CJ vein from
the base of the neck to the jugular bifurcation.
Through a side branch, the vein was cannulated
with a 24-gauge catheter. The animal was systemi-
cally heparinized with 1000 units of heparin as an
intravenous bolus, and proximal and distal control
of the vein segment was obtained with microvascu-
lar clamps. The isolated vein segment was rinsed
with M-199 and then gently distended with 200 to
400 µL of vector solution. The vector concentra-
tions used were: AD-LacZ (2·108 to 1·109), AD-
GFP and AAV-GFP (1·109), and AAV-LacZ (1·109
to 1·1010); all titers were in units of infective parti-
cles/mL. Multiplicity of infection (MOI) for the
target endothelium was estimated to range from
102 to 104 (102 to 103 for AD; 103 to 104 for
AAV) at these viral concentrations. Infections were
performed bilaterally in 41 of the animals and uni-
laterally in 10 of the animals.
In experiments planned for subsequent ex vivo
monocyte adhesion, a strictly bilateral protocol was
used, with AD-GFP exposure on one side and AAV-
GFP in the contralateral vein. In this distinct subset
of experiments, the vector concentrations were kept
constant at 1·109 for both types. As an internal con-
trol on each side, a distal segment of internal jugular
(IJ) vein was similarly isolated, rinsed, and gently
dilated with infusion of the delivery medium (M-
199) for the same interval. Microvascular clamps at
the jugular bifurcation ensured complete separation
between vector-treated (CJ) and sham-infected (IJ)
segments. In addition, flushing and release of the
clamps was performed in a strictly cephalad-to-cau-
dad fashion, to minimize the possibility of backwash
of vector particles into the control IJ segment. The
sham-infected segment subsequently served as a
control for the adhesion assay.
After 30 minutes of incubation with gentle dis-
tension, the vector solution (or vehicle) was with-
drawn, the vein segment was rinsed copiously with
M-199, and the patency of the jugular vein was
assessed after unclamping. The neck incision was
closed with running 4-0 Vicryl suture, and the ani-
mal recovered after receiving a dose of analgesic (flu-
nixin, 1-2 mg/kg intramuscularly; Henry Schein).
Animals were placed in an isolation room for 24
hours after infection, in accordance with institution-
al protocols. After viral exposure, animals were mon-
itored daily by both the investigators and veterinary
staff. General observations on activity level, food
and water intake, and fecal output were recorded.
Harvest of vein segments. Vein segments were
harvested at 2, 7, 14, and more than 28 days after
exposure to the viral particles. Animals were similarly
anesthetized, and the midline incisions were
reopened. After the patency of the neck veins was
assessed, the animal was heparinized (1000 units
intravenously) and subsequently killed with an over-
dose of anesthetic. In experiments involving AD-
LacZ or AAV-LacZ, in which X-gal staining was used
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for evaluation of transgene expression, veins were
perfusion-fixed with 400 mL of 2.5% glutaraldehyde
(Sigma) after distal cannulation. All other vein seg-
ments were harvested fresh and either immediately
snap frozen (RNA isolation, immunohistochemistry)
or processed for ex vivo monocyte adhesion.
Analysis of transgene expression
X-gal staining. The expression of β-D-galactosi-
dase in vein segments exposed to the LacZ vectors was
assessed by means of incubation with the chromogenic
substrate 5-bromo-4-choloro-3-indolyl-β-D-galac-
topyranoside (X-Gal, Sigma). In brief, glutaraldehyde-
fixed vein segments were washed with calcium/mag-
nesium-free phosphate-buffered saline (PBS-CMF),
rinsed with 1 mmol/L MgCl2 (in PBS-CMF), and
then incubated at 37°C for 2 to 4 hours in a solution
containing X-gal (1 mg/mL) with 1 mmol/L MgCl2,
1.64 gm/mL K3Fe(CN)6, and 2.1 gm/mL
K4Fe(CN)6·3H2O in PBS-CMF.19 Cleavage of this
substrate by β-D-galactosidase yields a blue precipitate,
which results in dense nuclear staining of transduced
cells. The vein segments were then cut along their lon-
gitudinal axes and examined with a stereomicroscope
(SMZ-10A, Nikon, Melville, NY) at varying magnifi-
cations. The surface area of positive (blue)-stained
endothelial cells was estimated and reported as a per-
centage of the total surface area transduced. In the case
of AAV-LacZ infections, more precise quantitation was
obtained by means of direct counts of positive-staining
cells on the vessel surface. Specimens were examined
on the stereomicroscope, and blue-stained cells were
counted in six high-power fields (49×, grid area 7
mm2) per vessel. An estimate of percentage was then
made by approximating the native endothelial cell
density at 105 cells/cm2. Cryostat sections (6 µm)
were also examined for localization of positive-staining
cells within the vein wall.
Direct fluorescence of green fluorescent pro-
tein. Portions of the vein segments exposed to GFP
vectors were opened longitudinally, mounted
between glass slides, and viewed on a fluorescent
microscope (Nikon) with fluorescein isothiocyanate
optics.
RNA analysis: reverse transcriptase-poly-
merase chain reaction. GFP expression was primar-
ily assessed by means of reverse transcriptase-poly-
merase chain reaction (RT-PCR). Freshly harvested
vein segments were snap frozen, and total RNA was
extracted by using TRIzol (GIBCO) per the manu-
facturer’s protocol. One microgram of total RNA
was digested with DNAse I (1 IU, GIBCO) for 15
minutes at 22°C, and the enzyme was then inactivat-
ed by the addition of 2.5 mmol/L EDTA and incu-
bation for 10 minutes at 65°C. The resulting RNA (1
µg) was then reverse transcribed by using a first-
strand complementary DNA (cDNA) synthesis kit,
which uses Moloney Murine Leukemia Virus reverse
transcriptase (Amersham Pharmacia Biotech,
Piscataway, NJ). Quality of the cDNA product was
tested by means of PCR with glyceraldehyde phos-
phate dehydrogenase–specific probes (GeneChecker,
InVitrogen, Carlsbad, Calif).
PCR amplification of the GFP sequence from har-
vested cDNAs used these primers: primer 1 (forward)
5’-AGTCCGCCCTGAGCAAAGA-3’ and primer 2
(reverse) 5’-TCACGAACTCCAGCAGGACC-3’.
These primers amplify a 63-base pair fragment from
the GFP gene. Five microliters of cDNA was added
to this PCR reaction mixture: 10× buffer (5 µL),
primer 1 (2 µL), primer 2 (2 µL), dNTP mixture (1
µL) 50× enzyme (1 µL; AdvanTaq DNA poly-
merase, Clontech, Palo Alto, Calif), and ddH2O (34
µL), for a total reaction volume of 50 µL. PCR was
completed by first denaturing at 95°C for 5 minutes,
followed by 25 cycles of denaturation (95°C for 30
seconds), annealing (62°C for 30 seconds), and
polymerization (72°C for 30 seconds), concluding
with extension at 72°C for 7 minutes. The reaction
products were then resolved on a 4% agarose gel,
along with appropriate positive (GFP-containing
plasmid) and negative (no template added) controls.
Ex vivo monocyte adhesion assay 
Monocytic THP-1 cells (American Type Culture
Collection, Manassas, Va) were maintained in com-
plete RPMI 1640 medium (GIBCO) supplemented
with 10% (v/v) fetal bovine serum, 0.2 mmol/L L-
glutamine, and antibiotics. Adhesion assays were
performed essentially as previously described.20 In
brief, an aliquot of THP-1 cells (1·107/mL) was
metabolically labeled with 200 µCi of Na251CrO4
(New England Nuclear Life Science Products,
Boston, Mass) for 1 hour at 37°C. The cells were
activated with 10 µmol/L formyl-methionyl-leucyl-
phenylalanine (fMLP, Sigma) and 2.5 mmol/L
CaCl2 for 30 minutes at 22°C. Freshly explanted
vein segments were cannulated and gently irrigated
with M-199 to wash away blood. The proximal end
of the vein was ligated, and the labeled THP-1 cells
were infused. The control (sham-infected IJ vein
exposed to medium only) and experimental (CJ vein
exposed to vector) segments were simultaneously
exposed to the same activated monocyte prepara-
tion. Vein segments were incubated with THP-1
cells at 37°C for 1 hour, then gently flushed with
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PBS (1 mL/min) by using a programmable infusion
pump (Harvard Apparatus, South Natick, Mass).
The external surfaces were also washed copiously
with PBS. Rings were carefully cut from the mid-
portion of the sham-infected and experimental vein
segments, measured with calipers to calculate surface
area, minced, and solubilized in 1% Triton X-100
(Sigma) and 10% sodium dodecyl sulfate (American
Bioanalytical, Natick, Mass). After the addition of
scintillant, bound radioactivity was measured in a
scintillation counter. An aliquot of labeled THP-1
cells was counted to calculate cpm/cell. Adhesion
was then quantitated as: (total specimen counts) ÷
(cpm/cell) ÷ surface area (cm2). The total number
of adherent THP-1 cells/cm2 for vector-treated seg-
ments was then normalized by dividing the values
obtained from the respective control segments,
yielding a relative adhesion ratio for each vector-
exposed specimen.
Immunohistochemistry
Rings cut from freshly harvested veins were
embedded in optimal cutting temperature (OCT)
compound (Sakura Finetek, Torrance, Calif) and
snap frozen in liquid nitrogen. Cryostat sections
were cut at 6-µm thicknesses and adhered to coated
glass slides (VWR Scientific, Media, Pa). Sections
were fixed in acetone at 4°C for 15 minutes,
quenched in 3% H2O2, and blocked with 10% 
normal horse serum for 1 hour at room tempera-
ture. Primary antibodies used were to CD31
(JC/70A, mouse anti-human IgG1, 1:50 dilution;
Dako, Carpentier, Calif), ICAM-1 (Rb 2/3, mouse
anti-rabbit IgG1, 1:150; donated by Dr M.
Cybulsky21), and RAM-11 (mouse anti-rabbit IgG1,
1:500; Dako). After incubation with the primary
antibodies at 22°C for 1 to 2 hours, the specimens
were washed, vacuum dried, and secondary antibody
(1:100 biotinylated horse anti-mouse; Vector
Laboratories, Burlingame, Calif) was applied for 1
hour at 22°C. Visualization of the primary antibody
was performed by using an avidin-biotin-peroxidase
complex (ABC Kit, Vector), followed by exposure to
3-amino-9-ethylcarbazole (AEC Kit, Vector).
Counterstaining was performed by using Gill’s
hematoxylin (Sigma).
Statistical analysis
Monocyte adhesion to vector-treated vein seg-
ments at different time points was compared by
using analysis of variance. Significance was achieved
at a P value less than .05.
RESULTS
A total of 51 rabbits underwent the infection
protocol, from which 91 vector-treated vein seg-
ments were subsequently harvested. Of these, 20
vein segments were exposed to AD-LacZ, 21 vein
segments were exposed to AD-GFP, 29 vein seg-
ments received AAV-GFP, and 21 vein segments
were treated with AAV-LacZ. There were no deaths
or major systemic adverse effects observed after viral
infection. At the outset of the experiments, two early
cases of vein thrombosis occurred, presumably
caused by technical difficulties; those animals were
excluded from this study. All other veins harvested
and included in this report were patent when the
animals were killed.
Transgene expression
β-Galactosidase–containing vectors. AD-
LacZ–infected vein segments demonstrated a high
percentage of positive X-gal staining on the luminal
surface (mean, 60% ± 9%; median, 70%; range, 10%
to > 90%) on postinfection day 2 (N = 14 veins; Fig
2, A). Some variability was noted, with three of 14
segments demonstrating a low percentage (10%-
15%) of luminal staining; this was believed to be
caused by technical factors, because the range of
viral concentrations used was narrow. On cross sec-
tion, the infection appeared almost completely limit-
ed to the endothelial cells (Fig 2, A, inset). At later
time points, LacZ-positive staining dropped precipi-
tously in the AD-treated veins to 28% ± 10% and 0%
of the surface on postexposure days 7 (N = 2) and
14 (N = 3; Fig 2, C), respectively.
In contrast, X-gal staining of AAV-LacZ infected
veins revealed a pattern of delayed increase in trans-
gene expression from day 2 through day 14 and
beyond, with persistence of positive-staining cells at
the latest time points examined (Fig 2, D, E, F). At
the earliest time points (day 2, N = 6 veins; Fig 2,
D), LacZ-positive cells were found in small focal
patches and appeared to consist of both endothelial
(rounded, longitudinally oriented) and underlying
smooth muscle (spindle, oriented perpendicular to
flow) cells. By days 7 (N = 4) and 14 (N = 6; Fig 2,
E), both overall staining and the percentage of trans-
duced endothelial cells on the surface increased
(maximal staining approximately 10% of surface on
day 14). Vessels explanted 28 to 40 days postinfec-
tion (N = 6) revealed scattered areas of positive
staining, reaching a maximum of approximately 14%
of the surface in one discrete segment of a day-39
explanted vein (Fig 2, F). The results of the direct
cell counts are illustrated in the Table. Cross sections
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taken from AAV-LacZ exposed vessels at 14 to 40
days revealed blue-stained cells on the luminal sur-
face, within the media, and to a lesser degree in the
adventitia (inset, Fig 2, F).
Green fluorescent protein–containing vectors.
Direct examination of GFP-infected veins with fluo-
rescent microscopy revealed extensive luminal cover-
age, with fluorescent-green cells in AD-GFP treated
veins on postinfection day 2 (N = 9; Fig 2, B). All
other specimens examined in this fashion were neg-
ative for direct visualization of the fluorescent
reporter gene.
PCR analysis of RNA isolated from treated veins
is demonstrated in Fig 3. All samples (both AD and
AAV) examined on postinfection day 2 revealed the
presence of the 63-bp GFP sequence product, with
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Fig 2. Analysis of rabbit jugular veins after exposure to adenovirus (A, B, C) or adeno-associated virus
(D, E, F) vectors. Specimens were explanted 2 days (A, B) and 14 days (C) after exposure to aden-
ovirus vectors (1·109/mL; β-galactosidase [A, C]; green fluorescent protein [B]). A, Inset is a repre-
sentative area on cross section, demonstrating localization of blue staining to the endothelial monolay-
er (magnification, 1000×). B, En-face fluorescent microscopy of an adenovirus-green fluorescent pro-
tein infected vein is shown. Representative areas of adeno-associated virus-β-galactosidase (1·109/mL)
infected veins are shown on days 2 (D), 14 (E), and 39 (F) postexposure. F, Inset (magnification, 400×;
L, lumen) is a cross section from a densely stained area, demonstrating positive-staining endothelial and
smooth muscle cells at day 39. (Magnifications: A and C, 7.5×; B, 200×; D, 20×; E and F, 49×).
Approximate percentage of X-gal positive cells on the luminal surface of adeno-associated virus-β-galactosi-
dase infected veins (obtained by direct cell counts)
Postinfection day Mean (± SEM) % positive Range (%, 6 HPFs per vessel)
2 1.0 ± 0.3 0 to 2.9
7 to 8 2.9 ± 0.8 0 to 8.5
14 to 15 4.3 ± 0.8 0.7 to 9.6
> 30 5.7 ± 1.1 1.4 to 13.6
P < .05 for day 2 versus all other time points and for day 7 and 8 versus days beyond 30 days.
HPFs, High-power fields.
or without prior reverse transcription of the sample.
Thus, DNA containing the GFP sequence was pre-
sent in all such samples, representing either viral par-
ticles per se or target cell DNA in such quantity or
form so as to render DNAse I digestion incomplete.
(DNAse I is relatively inefficient at digesting single-
strand DNA genomes contained in AAV virions.
Previous studies in other model systems have
demonstrated a process of conversion of single-
strand DNA to double-strand DNA in AAV-infected
cells, which takes place in days to weeks.22) Control
(sham-infected) veins and remote organs, such as
testicles (shown) and ovaries (not shown), were neg-
ative for the GFP product.
The kinetics observed with X-gal staining, at the
messenger RNA level, were extended and confirmed
by means of PCR analysis of specimens from later
time points. AD-GFP isolates at day 7 and 14 were
slightly variable, but mostly positive for reverse-tran-
scribed samples; non-RT treated specimens were
universally negative at this time point, consistent
with complete DNAse I digestion. AD-infected sam-
ples at day 30 were negative. In contrast, AAV-
infected veins revealed the GFP product in both
(negative RT and positive RT) samples at 7 days,
subsequently converting to strictly messenger RNA
(positive RT) forms at days 14 and beyond.
Local inflammatory response
Ex vivo monocyte adhesion. Vein segments
exposed to AD showed an early (postinfection day 2),
significant increase (2.7-fold) in THP-1 adhesion, as
compared with sham and AAV-infected (0.8-fold; P <
.05) vessels. The early increase in relative adhesiveness
seen with AD infection is reduced to baseline at 7 and
14 days (P < .05 for day 2 vs days 7 and 14; Fig 4).
AAV exposure did not result in a discernible increase
in monocyte adhesion relative to sham-infected seg-
ments at any of the time points examined.
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Fig 3. Reverse transcriptase-polymerase chain reaction
analysis of the green fluorescent protein transgene in tar-
get tissue. A, Representative of adeno-associated virus-
infected specimens (day 2 , N = 3; day 7 , N = 1; day 14,
N = 2; day 30, N = 3). B, Adenovirus specimens (day 2,
N = 3; day 7, N = 2; day 14, N = 2; day 30, N = 2). RNA
was isolated from veins on the indicated days after viral
exposure. Polymerase chain reaction amplification was
performed, by using both reverse transcribed (+) and non-
reverse transcribed (–) templates (paired lanes for each tis-
sue sample). M, Size markers (50 bp); P, green fluorescent
protein-containing plasmid control; V, control (uninfect-
ed) jugular vein; T, testicle from an experimental animal.
Fig 4. Results of ex vivo THP-1 adhesion assays,
expressed as a ratio to sham-infected vein segments on the
indicated days after vector exposure. Adhesion to adeno-
virus-infected veins on postexposure day 2 was significant-
ly increased (P < .05), as compared with adeno-associated
virus-treated (AAV) veins and adenovirus infection at all
other time points. POD, Postexposure day.
A
B
Histology and immunohistochemistry. Endo-
thelial integrity was assessed by staining for the
endothelial cell-specific marker CD31, which
demonstrated an intact monolayer at all the time
points examined, regardless of the vector used (Fig
5, A). Histologic examination of specimens harvest-
ed at days 2, 7, and 30 (Fig 5, E, F) revealed an
intact vein wall without discernible intimal thicken-
ing. A modest adventitial inflammatory reaction was
present and was not discernibly different between
AD- and AAV-treated veins. Staining for ICAM-1
revealed expression primarily limited to the 
endothelium and adventitia at all time points for
both vectors (Fig 5, B and D). RAM-11 positive
macrophages were seen infrequently and were limit-
ed to the adventitia (Fig 5, C, demonstrates the
absence of macrophages in AAV day 2 specimen). In
general, the small numbers of vector-specific samples
at each time point precluded quantitative compar-
isons between AD and AAV, although as a group the
staining patterns observed with this antibody panel
were fairly uniform.
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Fig 5. Histologic and immunohistochemical analysis of explanted veins after aden-
ovirus or adeno-associated virus mediated gene transfer. A, B, C, Vein specimen har-
vested 2 days after adeno-associated virus-green fluorescent protein exposure. A,
CD31 stain; B, ICAM-1 stain; and C, RAM-11 stain (all magnifications, 100×). D, An
adeno-associated virus-green fluorescent protein exposed vein on day 7, ICAM-1 stain
(magnification, 100×; inset magnification, 1000×). E (adeno-associated virus-green
fluorescent protein) and F (adenovirus-green fluorescent protein), Representative his-
tologic sections from a 30-day explanted vein, stained only with hematoxylin (magni-
fication, 40×).
DISCUSSION
This study demonstrated successful gene transfer
to rabbit jugular veins in situ with both AD and AAV
vectors, without discernible major toxicity. A 30-
minute intraluminal exposure protocol, easily trans-
ferable to a clinical intraoperative setting, was used.
Lack of thrombogenicity at the viral concentrations
used is an important finding, particularly given the
in situ venous setting of these experiments. Our
results with AAV-mediated gene transfer demon-
strate low overall efficiency, a unique pattern of gene
expression marked by delayed-onset and long-term
persistence, and a lack of discernible effect on adhe-
siveness for activated monocytes. Overall, the results
confirm the known limitations of AD-mediated
transfer—transient expression and local inflamma-
tion—and reveal a significant potential for AAV vec-
tors based on prolonged expression and minimal
apparent host response.
Recombinant, replication-deficient AD vectors
can be produced in high titers and are efficient at
infecting quiescent (eg, endothelial) cells.10,23 In
other models of vascular delivery, transgene expres-
sion with AD vectors has generally been limited to the
first 2 weeks after infection, similar to the results
obtained here.24-26 This is widely believed to be
caused by both the intrinsic properties of AD (non-
integrating life cycle) and a vigorous host response
directed at both external viral proteins and the ongo-
ing transcription of native AD sequences in infected
cells. In the context of vein graft therapy, the inflam-
matory response to AD may be of particular concern.
AD-mediated gene transfer to normal arteries has
been shown to induce endothelial activation, inflam-
matory cell recruitment, and subsequent intimal
hyperplasia.11,27,28 Both early neutrophil-dominat-
ed29,30 and late lymphocyte-predominant respons-
es31-33 and humoral responses to AD vectors34 have
been described. Our data also demonstrated an
enhanced adhesiveness of vein segments for activated
monocytes at early times after AD exposure.
Monocyte recruitment has been implicated as an
important feature of atherosclerosis35 and may also
play a significant role in vein graft hyperplasia.36,37 In
contrast to Newman et al,11 we did not observe any
measurable intimal hyperplasia in AD-exposed veins at
30 days; however, the number of samples examined
was small (N = 4). Our experimental model differed
from theirs both in the use of vein (as opposed to
artery) and the significantly reduced (log-fold) AD
viral concentration used. Despite these apparent
proinflammatory effects, other studies that used AD
vectors expressing genes designed to target intimal
hyperplasia (ie, cell cycle regulatory genes38) have
yielded promising results, suggesting that the choice
of a gene product of suitable potency may yield a net
favorable outcome.
Recombinant AAV vectors, based on AAV
serotype 2, have been under investigation since the
early 1980s. AAV, a member of the parvovirus fami-
ly, contains a single-strand DNA genome of 4679
bases and is nonpathogenic in humans.39,40 Wild-
type AAV requires both host cell factors and coin-
fection with other viruses (eg, adenovirus, her-
pesvirus) to cause a lytic infection.41 In the absence
of such helper viruses, AAV can integrate stably into
the host cell DNA.42,43 Stable integration of AAV
vectors has been demonstrated in a variety of cell
lines and tissues, most notably muscle, liver, and
central nervous system tissues. Studies in immuno-
competent animals have documented persistent
transgene expression beyond 1 year.12,13,15
Cardiovascular applications for AAV-mediated gene
delivery have been the subject of a small number of
recent reports.44-46 These earlier studies were char-
acterized by a disappointingly low efficiency of gene
transfer; however, low titer viral preparations and
early end-point analysis are critical differences in
comparison with the data reported here.
AAV is capable of infecting a wide variety of cell
types; recent studies have implicated several compo-
nents to the putative surface receptor, including
heparan sulfate proteoglycans (HSGAGs), the FGF
receptor, and the αvβ5 integrin.47-49 The interaction
with HSGAGs may be of particular relevance to the
application under consideration, because the pres-
ence of soluble heparin results in profound compet-
itive inhibition of AAV infection in vitro.47 In the
study cited, heparin inhibition was nearly complete
at concentrations roughly one tenth of those
encountered in the bloodstream after conventional
therapeutic heparin administration. In the present
series of experiments, vein isolation was achieved
after systemic heparinization; although segments
were rinsed copiously with nonheparin-containing
medium, residual bound heparin may have inter-
fered with AAV adsorption. Further studies are
underway to specifically address the potential effects
of heparin in this model.
Consistent with the results of other in vivo stud-
ies,50,51 a pattern of delayed increase and long-term
persistence of AAV-mediated gene expression was
noted in our study. To our knowledge, this report
constitutes the first description of the time course of
AAV-mediated gene expression in veins. One poten-
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tial rate-limiting factor in AAV expression appears to
be the conversion from a single-strand virus to a
transcriptionally active doublestrand template that
can then be integrated into the host genome and
stably maintained.52 This process may be accelerated
by certain adenoviral proteins and by toxic physical
or chemical agents.52,53 There was a shift in the cel-
lular pattern of staining observed in AAV-LacZ
infected veins, with an increasing proportion of
endothelial expression observed from 2 to 14 days.
A high percentage of the relatively few positive cells
at day 2 appeared to be smooth muscle cells, an
observation which may reflect a differential permis-
sivity for AAV between these two cell types. Of note,
all the vector constructs in these experiments used a
CMV promoter; different results might be obtained
with other generic or tissue-specific promoters.
The relative lack of immunogenicity represents
an important potential advantage of AAV and was
reflected in our study in the ex vivo monocyte adhe-
sion data and the histologic examination. Unlike
adenoviral vectors, AAV constructs do not include
endogenous viral open reading frames that may elic-
it an immune response. Other potential explanations
include the recent observation that AAV virions
infect antigen-presenting cells quite poorly.14
Conversely, prior exposure to wild-type AAV is
responsible for the presence of neutralizing antibod-
ies in as much as 40% to 50% of the population,54
which may be of significant practical importance for
clinical trials. Engineering of stable packaging cell
lines, improvement in yield of purification steps, and
better standardization are active areas in AAV vector
development that are likely to result in improved
reagents and more consistent results. Further studies
in vein graft models should be undertaken to exam-
ine the effects of higher viral titer, adjuvant treat-
ments to enhance second-strand synthesis, and alter-
native regulatory elements on AAV-mediated gene
expression.
In conclusion, gene delivery to vein segments
may be accomplished in a clinically relevant time
frame (less than 30 minutes) by using currently avail-
able AD and AAV vectors. Further modifications of
these vectors, aimed at reducing the host response
and increasing both infectivity and expression by vas-
cular cells, will facilitate the development of genetic
interventions targeting bypass graft failure.
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